evipedia.ai
← Back

Fisetin for Health & Longevity

Evidence Review created on 09/09/2026 using AI4L / Opus 5

Also known as: 3,3’,4’,7-Tetrahydroxyflavone, 5-Deoxyquercetin, Natural Brown 1, Novusetin, Cognisetin

Motivation

Fisetin is a yellow plant pigment found in strawberries, apples, persimmons and onions, and now sold in capsules. Interest in it rests on one idea: that it can selectively kill worn-out cells that stop dividing but refuse to die, and that clearing those cells might slow some of the changes that arrive with age.

The compound itself is not new. It was first pulled from the wood of the smoke bush in the 1830s and used as a fabric dye, then studied for decades for its effects on brain cells. Its current reputation rests largely on work in mice, where dosing started late in life lengthened survival. Whether anything similar happens in people is still open, and human testing began only recently.

This review examines what is known about fisetin: how it is thought to work, what human and animal studies show for benefit and for harm, how much of a swallowed dose actually reaches the body, the doses and schedules in use, what can be measured, and where the evidence is thin, conflicting or simply absent.

Benefits - Risks - Protocol - Conclusion

Expert overviews of fisetin and of cellular senescence — the state in which damaged cells stop dividing yet resist dying — and of senolytics, the compounds that clear them.

Andrew Huberman’s platform returned no content on fisetin, and Chris Kresser’s only match is a general phytochemicals article that mentions the compound in passing without discussing it; neither could therefore be represented here.

Grokipedia

  • Fisetin

    A structured overview of fisetin’s chemistry, natural sources, biosynthesis and metabolism, pharmacology and registered clinical trials, including the human bioavailability figures for the formulated product.

Examine

No Examine article exists for fisetin. A direct search of examine.com returns no results, and the conventional supplement page address returns a not-found error.

ConsumerLab

Systematic Reviews

Systematic reviews of fisetin, all of which synthesise laboratory and animal work rather than human trials.

The trade-off at stake is between fisetin’s claimed longevity benefit and its principal cost, which is unknown long-term safety at doses far above dietary intake. Systematic reviews exist for the benefit side across several organ systems; none exists for the risk side, and that half of the trade-off is unrepresented in the published synthesis literature.

Mechanism of Action

Fisetin is a flavonol — the plant-pigment family that also includes quercetin — and acts on several targets.

Its headline action is senolytic. Senescent cells survive by leaning on anti-death proteins, chiefly BCL-xL (a protein that blocks a cell’s self-destruct program); fisetin interferes with that dependence and with PI3K/AKT (a survival-signalling pathway), tipping such cells into programmed death while largely sparing healthy neighbours. It is also senomorphic, quieting the inflammatory secretions of the cells it does not kill by blocking NF-κB (a master switch for inflammatory genes). A competing account holds that fisetin’s effects are ordinary antioxidant and anti-inflammatory chemistry — activation of Nrf2 (a switch that turns on the cell’s antioxidant defences), scavenging of reactive oxygen species (unstable oxygen molecules), and modulation of AMPK (an enzyme that senses low cellular energy), mTOR (a growth-signalling protein) and SIRT1 (a repair-associated protein) — with no true killing of senescent cells required. Both readings fit the animal data.

Pharmacologically, fisetin behaves like a food polyphenol rather than a drug. Oral absorption is poor: gut and liver enzymes of the UGT and SULT families (which attach sugar or sulfate groups so a compound can be excreted) capture it almost immediately, and blood carries mainly sulfates, glucuronides and geraldol, an O-methylated metabolite. Parent fisetin is transient, with a plasma half-life of a few hours. Distribution is wide but concentrations are low; rodent work shows brain penetration. Fisetin selectively inhibits CYP2C8 (a liver enzyme that clears several drugs) while sparing other cytochromes.

Historical Context & Evolution

Fisetin was first isolated in 1833 from the wood of the smoke bush (Cotinus coggygria), and its structure was settled in the 1890s by Stanisław Kostanecki. Its original use had nothing to do with health: as the dyestuff “young fustic” it coloured textiles, and it survives as a marker compound used to date carpets and fabrics.

Biomedical interest began in the 2000s at the Salk Institute, where Pamela Maher’s group reported that fisetin promoted nerve-cell signalling and enhanced memory in mice; the institute holds a patent covering fisetin as a memory enhancer. Through that decade it was studied as a general antioxidant and anticancer flavonol.

The turn came in 2018, when a Scripps–Mayo collaboration screened ten flavonoids for the ability to destroy senescent cells, found fisetin the most potent, and reported reduced senescence markers plus extended median and maximum lifespan in old mice. That paper reframed fisetin as a longevity compound and prompted the first human trials.

The picture has since become less settled rather than more. The National Institute on Aging’s Interventions Testing Program, which runs compounds through genetically heterogeneous mice at three independent sites, reported in 2024 that fisetin did not significantly affect lifespan in either sex at the doses and schedules used. Neither result has been withdrawn. The 2018 finding stands in its own strain and dosing schedule; the program’s null stands in a design built to resist single-laboratory effects. Which of the two generalises to humans remains unknown.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint and no validated clinical surrogate has been reproduced across more than one randomised trial of fisetin — the human evidence consists of single small trials, each in a different population and measuring a different outcome.

Medium 🟩 🟩

Lower Systemic Inflammation

Fisetin blunts inflammatory signalling by inhibiting NF-κB and by reducing the output of senescent cells. In a randomised controlled trial (RCT) in 37 people on chemotherapy for colorectal cancer, 100 mg daily for seven weeks lowered high-sensitivity C-reactive protein (hs-CRP, a general marker of body-wide inflammation) and interleukin-8, though only interleukin-8 beat placebo. A 12-week RCT in men with obesity found lower interleukin-6 and tumour necrosis factor-alpha with fisetin alone. Both populations carried disease.

Magnitude: Direction is consistent — inflammatory markers fall — but the published reports give significance values without effect sizes or absolute changes, so the literature reports no outcome figure; the reductions held at 100–200 mg daily over 7–12 weeks in people with active disease or obesity.

Improved Glucose Control and Insulin Sensitivity

Fisetin activates AMPK and dampens mTOR, the pattern seen with calorie restriction. In a 12-week RCT in men with obesity, 200 mg daily lowered fasting glucose, insulin and HOMA-IR (a calculated index of insulin resistance), with the largest falls when fisetin was combined with interval resistance-plus-aerobic training. A companion trial from the same group used a near-identical protocol but did not measure glucose handling, so the finding is unreplicated.

Magnitude: Fasting glucose, insulin and HOMA-IR fell significantly in every active arm including fisetin alone, and most in the fisetin-plus-training arm at 200 mg daily over 12 weeks; the report states significance values rather than absolute changes, so the literature reports no outcome figure.

Reduced Body Weight

Fisetin’s metabolic effects extend to body mass. In the 12-week trial in men with obesity, the fisetin-only arm lost significantly more weight than placebo, as did both training arms; body mass index fell significantly only when fisetin was combined with training. The proposed route is the same AMPK and anti-inflammatory signalling that moved insulin resistance. One trial, one sedentary male population, no replication.

Magnitude: Body mass index in the fisetin-plus-training arm fell between 0.17 and 3.76 kg/m² further than placebo; the fisetin-only arm reached significance for weight loss, but the report gives significance values rather than an absolute change for it.

Extended Thrombolysis Window in Acute Ischemic Stroke

In a double-blind placebo-controlled trial, adding fisetin to recombinant tissue plasminogen activator (rt-PA, a clot-dissolving drug) improved scores on the National Institutes of Health Stroke Scale (NIHSS, a standard measure of stroke severity) in patients treated late after symptom onset, alongside falls in matrix metalloproteinases 2 and 9 (enzymes that break down tissue scaffolding). This is the only randomised, placebo-controlled human fisetin trial with a clinical endpoint. It is single-centre, enrolled 192 patients with 62 in the delayed stratum, and describes acute hospital care rather than a longevity protocol.

Magnitude: Benefit appeared only in the delayed treatment strata, where fisetin lowered stroke-scale scores relative to placebo and shifted the treatment window from roughly three hours to five; the report gives significance and correlations but no effect size, so the literature reports no outcome figure.

Low 🟩

Improved Blood Lipids Alongside Exercise

In the 12-week obesity trial, low-density lipoprotein cholesterol, triglycerides and total cholesterol fell while high-density lipoprotein cholesterol rose in the fisetin-plus-training arm. The fisetin-only arm did not separate from placebo on lipids, and the design cannot isolate what fisetin added.

Magnitude: Direction favours the combined arm only; the report gives significance values without absolute lipid changes, so the literature reports no outcome figure for fisetin’s independent contribution.

Speculative 🟨

Reduction in Biological-Age Scores ⚠️ Conflicted

An uncontrolled open pilot gave ten adults over 50 500 mg daily for one week a month for six months, tracking an unvalidated epigenetic age test. Four improved, five worsened. Net reading: unresolved.

Senescent-Cell Clearance and Lifespan Extension ⚠️ Conflicted

Late-life intermittent dosing cut senescence markers in several tissues and extended median and maximum lifespan in mice; the independent Interventions Testing Program found no lifespan effect in either sex. Net reading: unreplicated.

Vascular and Endothelial Function

Intermittent fisetin restored artery function in old mice, partly by lowering CXCL12 (an inflammatory messenger released by senescent cells). No human vascular outcome has been published.

Physical Function and Frailty

In old mice, intermittent fisetin improved grip strength and frailty scores about as much as genetically removing senescent cells. Human frailty trials are running but unreported.

Bone and Cartilage Preservation

A systematic review of thirteen studies found fisetin protected bone density and cartilage across cell and animal models of osteoporosis and osteoarthritis. No human musculoskeletal outcome exists.

Neuroprotection and Memory

A systematic review found fisetin promoted nerve-cell signalling and blunted amyloid and oxidative injury in cell and rodent models; it is patented as a memory enhancer. No human cognitive trial has reported results.

Anticancer Activity

A systematic review of fifteen preclinical studies found fisetin suppressed prostate and bladder cancer cell growth. The authors note low expected toxicity, but no clinical trial has tested this in people.

Kidney Protection

A systematic review found fisetin protected against drug-, diabetes- and lupus-induced kidney injury in animal models. The authors state that safe and effective human doses remain undetermined.

Cardiac and Hepatic Protection From Reperfusion Injury

A systematic review found fisetin limited reperfusion damage in heart and liver models, alongside brain and kidney, through antioxidant and anti-inflammatory action. No human reperfusion outcome exists.

Benefit-Modifying Factors

  • Absorption genotype: Variants in UGT1A and SULT1A1, the enzymes that conjugate fisetin within minutes of absorption, plausibly set how much free compound circulates. No fisetin-specific pharmacogenetic study exists, so this remains inferred from flavonol handling generally.

  • Baseline inflammation: The two trials that moved inflammatory markers enrolled people with cancer or obesity and elevated starting values. Someone with an hs-CRP already below 0.5 mg/L has little headroom, and regression to the mean explains part of any observed drop.

  • Baseline glucose handling: Improvements in fasting insulin and HOMA-IR were largest in sedentary men with insulin resistance. Metabolically healthy individuals with normal insulin have not been studied, and no benefit should be assumed for them.

  • Sex: Mayo Clinic ran a separate frailty trial in older women, implying an expected sex difference, but no result has been published. In mice, the Interventions Testing Program found no lifespan effect in either sex.

  • Age and senescent-cell burden: Fisetin improved function in old mice and had no effect in young ones, consistent with a mechanism that needs an accumulated burden to act on. Benefit in a healthy 40-year-old is therefore mechanistically less plausible.

  • Pre-existing conditions: Osteoarthritis, chronic kidney disease and post-cancer frailty are the states in which fisetin trials are concentrated, because senescent-cell load is high. Benefit signals to date come from these populations, not from healthy adults.

  • Concurrent exercise: In both obesity trials the largest metabolic and lipid changes occurred when fisetin was paired with interval resistance and aerobic training, suggesting the compound modifies an exercise response rather than substituting for one.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been documented in more than one controlled trial of fisetin — the human safety record consists of short single trials and uncontrolled pilots, whose reported events (pain, headache, diarrhoea, leg cramping) have no comparator to be judged against.

Medium 🟥 🟥

No risk reaches Medium either: no single controlled trial and no consistent observational dataset has attributed a specific adverse outcome to fisetin — the signals below rest on isolated human reports, on related whole-plant extracts, or on laboratory work.

Low 🟥

Additive Blood-Pressure Lowering

Fisetin relaxes blood vessels and lowers arterial pressure in rodents. A ConsumerLab member taking antihypertensive medication reported several hours of reduced blood pressure after a dose. The concern is confined to people already on pressure-lowering drugs.

Magnitude: Not quantified in available studies. No controlled trial has measured blood pressure on fisetin in humans, so the only human signal is a single self-reported case.

Allergic Skin Reactions From Lacquer-Tree Material

Much commercial fisetin comes from the wood of Toxicodendron vernicifluum, which a phytochemistry review reports also carries urushiols, the poison-ivy allergens. A prospective study of a whole-plant extract recorded mild itching in one of 25 patients. Purified material carries little of this risk, but purity varies by manufacturer.

Magnitude: 1 of 25 patients (4%) developed non-severe pruritus (itching) attributed to the whole-plant extract; no reaction rate has been reported for purified or synthetic fisetin.

Transient Non-Serious Adverse Events

The completed carpal tunnel trial (registry results) recorded non-serious events in 15 of 40 participants: mostly increased pain, plus single cases of headache, loose bowels and leg cramping. No deaths or serious events occurred, and short pharmacokinetic dosing produced none. Without a placebo arm, disease progression cannot be separated.

Magnitude: 15 of 40 participants (37.5%) reported at least one non-serious event over 180 days, with increased pain in 7 and worsened symptom scores in 5; no deaths and no serious adverse events.

Speculative 🟨

Worsening of Biological-Age Scores ⚠️ Conflicted

In the only human study that tracked it, five of ten adults on 500 mg monthly pulses showed rising epigenetic age over six months. The pilot was uncontrolled and the assay unvalidated. Net reading: unresolved.

Increased Bleeding Risk With Anticoagulants and Antiplatelet Agents

Fisetin inhibited platelet clumping and protected rats from arterial clotting at 100 mg/kg daily. No human bleeding event has been reported; the concern is mechanistic and additive only.

Drug Interactions Through CYP2C8 Inhibition

In human liver preparations fisetin reversibly and selectively inhibited CYP2C8 at low micromolar concentrations. Whether circulating levels after an oral dose ever reach that range in people is untested.

Genotoxicity at High Concentrations

At 40–80 micromolar, fisetin broke DNA strands in glioblastoma cells and blunted DNA repair, activating p53 (the cell’s damage-response protein). Whether an oral dose reaches such concentrations in people is untested.

Altered Response to Concurrent Cancer Treatment

Fisetin kills tumour cells and has been paired with chemotherapy agents experimentally. No human data address whether adding it to an active regimen helps, hinders or does nothing.

Risk-Modifying Factors

  • Metabolising genotype: Reduced-function CYP2C8*3 carriers already clear paclitaxel and repaglinide slowly. Adding an inhibitor of the same enzyme is the situation in which fisetin’s laboratory interaction signal would matter most, if it matters at all.

  • Baseline platelet count and clotting markers: Anyone with a platelet count below the reference range, or on dual antiplatelet therapy, starts closer to the bleeding threshold that fisetin’s rodent antiplatelet activity would push against.

  • Baseline blood pressure: Individuals running low-normal pressures, or on multiple antihypertensive agents, have the least margin for the additive vasodilation seen in rodents and reported anecdotally.

  • Sex: No sex-specific adverse-event data exist for fisetin. Women were enrolled in a dedicated Mayo Clinic frailty trial, but its safety results are unpublished, so any sex difference in tolerability is currently unknown.

  • Pre-existing conditions: Active malignancy under treatment, bleeding disorders, and severe kidney or liver impairment are the states in which a poorly characterised polyphenol carries the most uncertainty, since none has been studied.

  • Age: Every human fisetin trial in the aging field enrols people over 50 or 65, so tolerability data — such as they are — apply to older adults. Nothing is known about multi-year exposure at any age.

  • Known plant allergy: A history of reaction to poison ivy, poison oak, sumac, mango skin or cashew shell marks sensitivity to the urushiol family present in the usual source plant.

Key Interactions & Contraindications

  • CYP2C8 substrates (paclitaxel, repaglinide, montelukast, rosiglitazone, amiodarone): Caution. Fisetin non-competitively inhibits this enzyme in human liver microsomes, which could raise substrate levels. Mitigation: separate dosing or omit fisetin during treatment cycles.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Caution. Rodent data show fisetin inhibits platelet aggregation and arterial thrombosis, giving an additive bleeding risk. Mitigation: avoid combination or monitor for bruising and bleeding.

  • Antihypertensives (amlodipine, lisinopril, losartan, hydrochlorothiazide): Caution. Fisetin is vasodilatory in animals and one user reported a transient blood-pressure drop. Consequence: symptomatic hypotension (blood pressure low enough to cause light-headedness). Mitigation: home blood-pressure logging during early cycles.

  • Glucose-lowering agents (metformin, glipizide, insulin): Caution. Fisetin lowered fasting glucose and insulin resistance in trials, so combination could over-correct. Consequence: hypoglycaemia (blood sugar dropping too low). Mitigation: monitor fasting glucose during the first two cycles.

  • Over-the-counter analgesics (ibuprofen, naproxen, low-dose aspirin): Caution. These already impair platelet function; adding fisetin’s antiplatelet activity compounds it. Consequence: gastrointestinal or bruising-type bleeding. Mitigation: avoid regular concurrent use.

  • Over-the-counter acid blockers and antacids (omeprazole, calcium carbonate): Caution. Reducing stomach acidity reduces dissolution of an already poorly soluble compound. Consequence: lost absorption. Mayo Clinic’s trial protocol requires holding proton pump inhibitors around each dosing window.

  • Supplement interactions (quercetin, curcumin, resveratrol, green tea catechins): Monitor. All are conjugated by the same UGT and SULT enzymes and compete for them, which may raise or lower free fisetin unpredictably. Mitigation: stagger dosing days.

  • Supplements with additive antiplatelet effect (fish oil, ginkgo, garlic, nattokinase, high-dose vitamin E): Caution. Each independently lengthens bleeding time; stacked with fisetin the effect compounds. Mitigation: avoid using several in the same window.

  • Supplements with additive blood-pressure lowering (beetroot nitrate, magnesium, hibiscus, potassium): Caution. Combined vasodilation can drop pressure further than intended, particularly in already-treated individuals. Consequence: dizziness on standing. Mitigation: introduce one agent at a time.

  • Other senolytic protocols (dasatinib plus quercetin): Caution. Overlapping mechanism with no combination safety data, and dasatinib carries its own toxicity. Consequence: unquantified additive risk. Mitigation: do not run protocols concurrently.

  • Cytotoxic chemotherapy and radiotherapy: Caution. Fisetin modifies tumour-cell sensitivity in laboratory models with no human evidence either way. Consequence: unpredictable interference with a treatment that matters. Mitigation: oncologist decision only.

Populations who should avoid Fisetin:

  • Pregnancy and lactation — no reproductive toxicity data exist at supplemental doses
  • Known urushiol-family allergy (poison ivy, oak, sumac, mango skin, cashew shell) where the product is a lacquer-tree extract
  • Active bleeding disorders, or platelet count below 100 ×10⁹/L
  • Scheduled surgery within 14 days
  • Severe hepatic impairment (Child-Pugh Class C) — conjugation and biliary excretion are the primary clearance routes
  • Advanced kidney disease (eGFR, a calculated measure of kidney filtration, below 30 mL/min/1.73 m²) outside a supervised trial
  • People under 18, in whom senescent-cell burden is low and no data exist
  • Active cancer treatment, unless the treating oncologist has approved it

Risk Mitigation Strategies

  • Purified or synthetic source: Selecting material standardised to at least 95% fisetin, rather than a crude lacquer-tree extract, minimises the urushiol carry-over that produced the one documented allergic reaction.

  • Separation from CYP2C8 substrates: Where paclitaxel, repaglinide, montelukast or rosiglitazone is in use, holding fisetin entirely — or dosing it on non-treatment days — avoids the enzyme inhibition seen in liver preparations.

  • Pre-procedure pause: Stopping fisetin 7–14 days before surgery, dental extraction or colonoscopy removes any additive antiplatelet effect during the period when bleeding risk is concentrated.

  • Home blood-pressure logging during the first cycles: For anyone on antihypertensive medication, checking seated pressure daily through the first two dosing cycles catches the additive drop reported anecdotally before it becomes symptomatic.

  • Intermittent rather than continuous dosing: A 2-day monthly or 1-week monthly schedule matches the mechanism and cuts total annual exposure roughly 10-fold, limiting the unstudied long-term-use risk.

  • Baseline and follow-up liver and kidney panels: Checking transaminases and estimated filtration rate before starting and at 3 months detects organ effects that no trial has been long or large enough to exclude.

  • No stacking with other antiplatelet supplements: Not combining fisetin with fish oil, ginkgo, garlic, nattokinase or high-dose curcumin in the same window prevents an additive bleeding tendency none of them carries alone.

Therapeutic Protocol

  • Intermittent high-dose schedule: The Mayo Clinic protocol used in the frailty and COVID-19 trials gives 20 mg/kg body weight daily for 2 consecutive days, repeated monthly — roughly 1,400 mg per day for a 70 kg adult.

  • Intermittent moderate-dose schedule: The pilot biological-age study used 500 mg daily for one week per month across six months, a schedule popular in longevity practice because it preserves the hit-and-run logic at a lower total dose.

  • Continuous low-dose schedule: The Copenhagen group’s trial in adults over 50 uses 100 mg daily for seven weeks, targeting chronic inflammation rather than senescent-cell clearance — a senomorphic rather than senolytic intent.

  • Typical commercial dose: Most retail products supply 50–150 mg per serving; ConsumerLab reports 50–150 mg daily as the range proposed as potentially beneficial in people, at roughly $11–15 per month.

  • Competing approaches: Mayo Clinic’s Kirkland and Tchkonia group popularised dasatinib plus quercetin as the reference senolytic; the Scripps and Minnesota group behind the 2018 paper favours fisetin alone; the Copenhagen group favours continuous low-dose. None has demonstrated superiority.

  • Best time of day: No chronobiology data exist for fisetin. Practice defaults to a morning dose with the day’s largest fat-containing meal, on the reasoning that solubility rather than clock time governs how much is absorbed.

  • Half-life: Parent fisetin is cleared within hours — it appears in serum only transiently during absorption before conjugation dominates — which is the pharmacological argument for pulsed rather than continuous dosing.

  • Single versus split dosing: High-dose intermittent protocols split the daily amount across two or three meals to spread the solubility-limited absorption; low-dose continuous protocols use a single daily capsule.

  • Formulation matters more than dose: A hydrogel formulation delivering 192 mg produced 27 times the total exposure of 1,000 mg of unformulated powder, so label milligrams are close to meaningless across products.

  • Genetic polymorphisms: No pharmacogenetic guidance exists. Reduced-function CYP2C8*3 carriers taking that enzyme’s substrates, and people with slow-conjugating UGT1A variants, are the plausible outliers, but neither has been tested with fisetin.

  • Sex-based differences: Mayo Clinic ran parallel frailty trials in mixed-sex and women-only cohorts, implying an anticipated difference; no results are published and no sex-specific dose has been proposed.

  • Age considerations: Every human protocol enrols adults over 50, and animal benefit appears only in old animals. For people at the older end of the range, the intermittent schedules are also the ones with the least cumulative exposure.

  • Baseline biomarkers: Elevated hs-CRP, interleukin-6 or suPAR (a blood marker of long-running inflammation) identify the inflammatory phenotype that trials select for. Those with unremarkable markers have no established target to move.

  • Pre-existing conditions: Osteoarthritis, chronic kidney disease, peripheral artery disease and post-cancer frailty are the states under active study; response outside them is extrapolation.

Discontinuation & Cycling

  • Not framed as lifelong: Every published fisetin protocol is finite — two days a month, one week a month, or seven weeks total. No protocol proposes uninterrupted daily use for years, and none has tested it.

  • No known withdrawal effects: Because fisetin has no receptor occupancy to lose and no adaptive downregulation has been described, stopping produces no recognised rebound. No trial has reported discontinuation symptoms.

  • No taper required: The compound clears within hours and the intermittent protocols already impose repeated abrupt stops, so tapering has no pharmacological rationale and is not described anywhere in the literature.

  • Cycling is the design, not an add-on: The hit-and-run rationale holds that senescent cells take months to reaccumulate, so pulsed dosing separated by weeks is expected to work as well as continuous exposure at far lower total intake.

  • Reassessment point: With no validated response marker, the practical stopping rule is the absence of movement in the inflammatory or metabolic markers that were elevated at baseline after two or three cycles.

Sourcing and Quality

  • Source plant carries an allergen: Most commercial fisetin is extracted from the heartwood of Toxicodendron vernicifluum or Rhus succedanea, both of which also contain urushiols. Synthetic or highly purified material sidesteps this entirely.

  • Standardisation percentage: The branded ingredients Cognisetin and Novusetin, both from Cyvex Nutrition, are Japanese wax tree extracts standardised to 95% fisetin. Products that state only “fisetin extract” without a percentage should be treated as unspecified.

  • Third-party testing: No fisetin product currently carries an NSF International, US Pharmacopeia (USP) or Informed Choice certification. A current certificate of analysis from an independent laboratory showing identity, potency, heavy metals and solvent residues is the practical substitute.

  • Bioavailability-enhanced formats: Fenugreek galactomannan hydrogel (Trigonella foenum-graecum fibre) raised total exposure 27-fold in a human crossover study; liposomal formats claim similar gains from animal data. Both carry a price premium.

  • Named products: Doctor’s Best and Swanson use Novusetin; Renue by Science sells a liposomal version; Life Extension sells the fenugreek hydrogel format. Life Extension co-authored the study underpinning that formulation’s absorption claim.

  • Powder versus capsule: Bulk fisetin powder is cheapest per gram but is nearly insoluble in water and oxidises on exposure to light and air. Capsules in opaque bottles with a dated expiry are the more reliable format.

Practical Considerations

  • Time to effect: Inflammatory and metabolic markers moved over 7 to 12 weeks in the trials that measured them. Nothing subjective has been shown to change on any timescale, so felt effects should not be expected.

  • Common pitfall — treating label milligrams as delivered dose: Unformulated fisetin is nearly insoluble and heavily conjugated on first pass. A 1,000 mg capsule can deliver a fraction of what 192 mg in a hydrogel does.

  • Common pitfall — importing the mouse lifespan number: The frequently quoted 10% lifespan gain comes from one mouse study started at 85 weeks of age and was not reproduced by the independent testing program.

  • Common pitfall — taking it on an empty stomach: Absorption depends on solubilisation. ConsumerLab’s guidance is to take fisetin with meals unless the product’s own label specifies otherwise.

  • Regulatory status: Fisetin is sold as a dietary supplement in the United States and is not approved as a drug by the US Food and Drug Administration (FDA) or any comparable agency. Clinical use is investigational only.

  • Cost and accessibility: Standard products run about $11–15 per month, rising to roughly $45 for combination or enhanced-absorption formats — inexpensive relative to most longevity interventions and available without prescription.

  • Structural funding asymmetry: Fisetin is unpatentable and cheap, while the senolytic it is benchmarked against, dasatinib, is a patented prescription drug. Neither insurers nor manufacturers gain from proving the cheap option works, so most trials are investigator- or supplement-industry funded.

Interaction with Foundational Habits

  • Sleep: No established direction. Fisetin has no sedative or stimulant activity and no trial has measured sleep as an outcome, though one ongoing study pairs it with urolithin A specifically to test sleep and aging biomarkers. Practically, dose timing appears irrelevant to sleep.

  • Nutrition: Direct and potentiating. Absorption depends on fat and on solubilisation, so taking fisetin with the day’s largest fat-containing meal is the single highest-yield habit. Dietary sources are trivial by comparison: strawberries lead at about 160 micrograms per gram, requiring roughly a pound to approach one capsule.

  • Exercise: Potentiating in the only trials that tested both. Twelve weeks of interval resistance plus aerobic training combined with 200 mg daily produced larger falls in inflammatory markers, insulin resistance and lipids than either alone. A theoretical concern that antioxidants blunt exercise adaptation has not been observed with fisetin.

  • Stress management: Indirect only. Chronic psychological stress raises the senescent-cell burden that fisetin is meant to reduce, so stress reduction acts on the same upstream driver. No trial has measured cortisol or any stress marker on fisetin.

Monitoring Protocol & Defining Success

Because fisetin has no validated response marker, monitoring is built around the outcomes human trials actually moved and around the organs a poorly characterised polyphenol could plausibly affect. A baseline panel drawn before the first dose covers systemic inflammation, glucose handling, lipids, liver enzymes, kidney function, a complete blood count with platelets, and seated blood pressure. Where an intermittent monthly schedule is used, the practical cadence is to repeat the inflammation and metabolic markers at 8–12 weeks and then every 6 months; liver and kidney panels once at 3 months and annually thereafter; and, for anyone already on antihypertensive medication, home blood pressure daily through the first two cycles. None of these is validated as a fisetin response marker, so the comparison that matters is each person’s own baseline rather than a population range.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
hs-CRP < 1.0 mg/L Primary inflammation marker moved in the human trials High-sensitivity C-reactive protein; the conventional low-risk cut-off of < 3.0 mg/L is three times looser; fast 12 hours and defer testing for 2 weeks after any infection, which distorts it
Interleukin-6 < 2.0 pg/mL Second inflammatory signal that fell with fisetin Conventional labs rarely offer a reference range; pair with hs-CRP and interpret as a trend, not a threshold
suPAR < 3.5 ng/mL Primary endpoint of the ongoing low-dose fisetin trial Soluble urokinase plasminogen activator receptor, a stable marker of chronic inflammation; less meal- and infection-sensitive than hs-CRP
Fasting insulin 2–6 µIU/mL Insulin resistance improved in both obesity trials Conventional reference runs up to about 25 µIU/mL, far above the functional target; requires a 10–12 hour fast; draw with glucose from the same sample so the resistance index can be calculated
HOMA-IR < 1.5 The composite index that actually moved Calculated from fasting insulin and glucose, not ordered separately; the conventional insulin-resistance threshold sits near 2.5; morning draw for consistency
Fasting glucose 75–86 mg/dL Fell in every active trial arm Conventional reference tops out at 99 mg/dL, well above the functional target; best paired with fasting insulin
HbA1c 4.8–5.3% Confirms that fasting changes reflect real glycaemic change Glycated haemoglobin, an average of roughly 3 months of blood sugar; conventional normal extends to 5.6%, above the functional target; no fasting required and unaffected by time of day
LDL cholesterol < 80 mg/dL Lipids shifted in the combined training arm Low-density lipoprotein cholesterol; conventional cut-off of 100 mg/dL is less stringent; fast 9–12 hours and pair with apolipoprotein B
ALT 10–26 U/L (women), 10–30 U/L (men) Detects liver effects no trial was long enough to exclude Alanine aminotransferase; conventional upper limits near 40–55 U/L are considerably looser; avoid intense exercise for 48 hours before the draw
eGFR > 90 mL/min/1.73 m² Kidney clearance safety check Estimated glomerular filtration rate, a calculated measure of kidney filtration; conventional normal starts at 60 mL/min/1.73 m², well below the functional target; creatinine rises transiently after heavy protein intake or exercise
Platelet count 175–250 ×10⁹/L Baseline for the theoretical antiplatelet effect Part of a complete blood count; the conventional reference of 150–450 ×10⁹/L is much wider; a low-normal starting value is the relevant flag before combining with anticoagulant or antiplatelet agents
Seated blood pressure 110–120 / 70–80 mmHg Catches additive vasodilation Measure after 5 minutes seated, same arm, same time of day; morning readings are the most comparable across weeks
Epigenetic age No established target — track the change from the individual’s own baseline The outcome the only human aging pilot measured Test-retest variation is large enough that a single reading means little; repeat on the same platform or not at all

Qualitative markers worth tracking alongside the panel:

  • Physical function — grip strength, chair-stand time, or usual walking pace, since these are the endpoints the human frailty trials chose
  • Joint comfort and morning stiffness, given the concentration of fisetin research in osteoarthritis
  • Energy and daytime fatigue, the outcome of the ongoing cancer-survivor pilot
  • Sleep quality and duration, so that the ongoing sleep trial’s premise can be checked against personal experience
  • Skin bruising or gum bleeding, the earliest practical signal of an additive antiplatelet effect
  • Any itching or rash within 48 hours of a dose, which would point at plant-derived contaminants rather than fisetin itself

Emerging Research

  • AFFIRM-LITE frailty trial: NCT03675724, a Mayo Clinic Phase 2 study in 40 frail older adults using 20 mg/kg daily for 2 consecutive days monthly, with frailty and inflammatory measures as endpoints. Enrolling by invitation since 2018 and still unreported.

  • Parallel trial in older women: NCT03430037 runs the same Phase 2 design in 40 older women, and is the only registered study positioned to answer whether fisetin’s effects differ by sex.

  • Vascular function in older adults: NCT06133634, a University of Colorado Boulder Phase 1/2 trial in 70 participants measuring endothelial function and arterial stiffness — the direct human test of the mouse artery findings.

  • Multimorbidity pilot: NCT06431932, a Phase 1/2 Copenhagen study in 60 healthy volunteers and older patients with multiple conditions, designed to settle dose and safety questions that the field has so far assumed rather than established.

  • Healthy aging trial: NCT07195318 enrols 120 healthy adults, and its published protocol tests 100 mg daily for 7 weeks against placebo with suPAR as the primary endpoint (Tavenier et al., 2026).

  • Peripheral artery disease: NCT06399809, a Northwestern Phase 2 trial in 34 participants testing whether reducing senescent cells improves walking impairment in peripheral artery disease — a functional endpoint rather than a marker.

  • Carpal tunnel syndrome: NCT05416515, a completed single-arm Mayo Clinic Phase 2 trial in 40 patients, posted registry results in December 2025: symptom scores fell 0.5 points at 60 days, with no placebo arm to compare against.

  • Pharmacokinetics in young versus old adults: NCT06796374 compares fisetin handling across 80 young and older participants, addressing the unexamined assumption that absorption and clearance are age-invariant.

  • Evidence that could weaken the case: The Interventions Testing Program’s null lifespan result (Harrison et al., 2024) is the strongest counterweight to the 2018 mouse finding, and the programme’s 2026 report shows the same design continuing to reject most candidates.

  • Formulation as a confounder: The 27-fold exposure difference between formulated and unformulated fisetin (Krishnakumar et al., 2022) means trials using different products may not be testing comparable interventions, which could explain divergent results independently of biology.

  • Mechanism under revision: Work identifying CXCL12 as a mediator of fisetin’s vascular effects (Mahoney et al., 2026) shifts the account from cell killing toward secretory suppression, a change that would alter which dosing schedule makes sense.

Conclusion

Fisetin is a plant pigment sold as a supplement on the strength of a single striking animal finding: that dosing started late in life cleared worn-out cells and lengthened survival in mice. That finding was not reproduced by the largest independent animal aging program, and no human study has yet measured survival, disease events or physical ability against a placebo over a meaningful stretch of time.

The human data that exist are small and short. Markers of inflammation and blood sugar control, and body weight, moved favourably in a handful of trials, mostly in people with illness or excess weight rather than in healthy adults working to extend good years. One small study of biological-age scores, with no comparison group, moved in both directions across its participants. Everything else — blood vessels, heart, liver, bone, brain, joints, kidneys and tumour cells — rests on cells and animals.

Safety looks unremarkable at the doses in use, though that reflects brief exposure in very few people rather than a clean long-term record. Absorption is poor unless the compound is reformulated, so the number on the label says little about what reaches tissue. Much of the enthusiastic material comes from companies that sell it, and the reference sources that discount it are working from the same thin evidence.

For someone willing to act on incomplete information, fisetin is cheap, apparently well tolerated, and unproven in people — a bet on a mechanism rather than on a demonstrated result.

Top - Benefits - Risks - Protocol